(Total Views: 852)
Posted On: 07/12/2024 12:02:11 AM
Post# of 154089
Quote:
After our preclinical glioblastoma trial, perhaps leronlimab can get added to the GBM AGILE platform trial.
Kazia's drug paxalisib is a PI3K inhibitor. Which is the start of the PI3K/AKT/mTOR pathway. No surprise that leronlimab does the same thing and more.
With the CRC trial I'm sure they'll track numerous biomarkers then finally the FDA will realize how broad acting leronlimab is in cancer.
(21)
(0)
